4th Middle East Pharmacoeconomics and Drug Policy Summit

Memo

As healthcare systems evolve, Pharmacoeconomics will remain a key discipline for guiding decisions that optimize outcomes, resource allocation, and the overall sustainability of healthcare. This Summit has been meticulously crafted to serve as a dynamic platform for thought leaders, policymakers, and key stakeholders to exchange insights, share experiences, in the areas focused on healthcare policy, the HEOR in healthcare decision making, economic evaluations, VBHC, the implications of HTA, responses to Real-World Evidence, collaboration, affordability, and equity in healthcare, that enhance patient outcomes, ensure accessibility to innovative therapies, and contribute to the sustainability of our healthcare infrastructure. URLs:Tickets: https://go.evvnt.com/2151117-1?pid=5569 Facebook: https://go.evvnt.com/2151117-3?pid=5569 Twitter: https://go.evvnt.com/2151117-4?pid=5569 Instagram: https://go.evvnt.com/2151117-5?pid=5569 Date and Time: On Fri, 23 Feb 2024 09:00 - Sat, 24 Feb 2024 17:00 Venue Details: Address Dubai Marina, 66 Al Marsa Street, Dubai, United Arab Emirates Prices:General Admission: AED 1.00,Pharma company: AED 1.00 Speakers: Ahmed Aljedai, Founding President, Saudi Society of Clinical Pharmacy, Professor, Colleges of Medicine and Pharmacy, Alfaisal University, Consultant Clinical Pharmacist, Solid Organ Transplant, Ministry of Health, KSA , Hajer Al-Mudaiheem Pharm.D., MSc. Clinical Pharmacy, CLSSBB, Advisor, Assistant Deputy for Therapeutic Supportive Services, Director, Drug Policy and Regulation Department, Ministry of Health, KSA - – confirmed , Anas Hamad PhD, MSc, DMS, BPharm, RPh, Director of Pharmacy Department, National Center forCancer Care and Research; Assistant Professor,College of Pharmacy, Qatar University, Qatar , Abdullah Thumairi, Associate professor Prince Sattam Bin Abdulaziz University, KSA , Mouna Jameleddine, Director of HTA Department of INEAS (Tunisia);Vice Chair of INAHTA International Networkof Agencies for HTA); Chair of the ISPOR HTA Roundtable for Middle East and Africa , Sara Al Dallal, President, Emirates Health Economics Society, Emirates Medical Association, UAE , Fabrizio Gianfrate Full Professor of Health Economics and Outcome Research, University of Ferrara and LUISS Business School Rome, Italy , Mary Kirollos Medical Technology Management Director, The Egyptian Authority for Unified Procurement, Medical Supply and The Management of Medical Technology Egypt , Mohamed Farghaly Consultant DHIC, Head of Insurance Policies and Health Economics, Dubai Health Authority, UAE , Suliman Alghnam Head of Population Health, King Abdulah International Medical Research Center KAIMRC, KSA , Tomasz Kluszczynski Frankfurt University, Germany; Warsaw University of Technology and Goethe Business School, Poland , Ahmed Seyam Director: Health Economics, and Health Systems Research – UHIA Health Economics, Health Systems, and Healthcare FinancingConsultant – MoHP, MoF, Cairo,Egypt , Gihan Hamdy Elsisi, Managing Director, HTA Office, Egypt , Dr. Maryam Alowayesh , Department of Pharmacy Practice- School of Pharmacy, Kuwait , Khuloud Bin Rafeea, Director of Drugs and Medical Products, Department of Health, Abu Dhabi, Abu Dhabi, UAE, Dr. Yasser Almeqbel Alqassim University , Mohammad Al Haidan from Saudi Health Council, KSA